Should an oral glucose tolerance test be performed routinely in all renal transplant recipients?

Kirsten A. Armstrong, Johannes B. Prins, Elaine M. Beller, Scott B. Campbell, Carmel M. Hawley, David W. Johnson, Nicole M. Isbel

Research output: Contribution to journalArticleResearchpeer-review

42 Citations (Scopus)

Abstract

Posttransplantation diabetes (PTD) contributes to cardiovascular disease and graft loss in renal transplant recipients (RTR). Current recommendations advise fasting blood glucose (FBG) as the screening and diagnostic test of choice for PTD. This study sought to determine (1) the predictive power of FBG with respect to 2-h blood glucose (2HBG) and (2) the prevalence of PTD using FBG and 2HBG compared with that using FBG alone, in prevalent RTR. A total of 200 RTR (mean age 52 yr; 59% male; median transplant duration 6.6 yr) who were >6 mo posttransplantation and had no known history of diabetes were studied. Patients with FBG

Original languageEnglish
Pages (from-to)100-108
Number of pages9
JournalJournal of the American Society of Nephrology : JASN
Volume1
Issue number1
DOIs
Publication statusPublished - Jan 2006
Externally publishedYes

Cite this

Armstrong, Kirsten A. ; Prins, Johannes B. ; Beller, Elaine M. ; Campbell, Scott B. ; Hawley, Carmel M. ; Johnson, David W. ; Isbel, Nicole M. / Should an oral glucose tolerance test be performed routinely in all renal transplant recipients?. In: Journal of the American Society of Nephrology : JASN. 2006 ; Vol. 1, No. 1. pp. 100-108.
@article{8a1482d756b249aeb1b6384468d15c38,
title = "Should an oral glucose tolerance test be performed routinely in all renal transplant recipients?",
abstract = "Posttransplantation diabetes (PTD) contributes to cardiovascular disease and graft loss in renal transplant recipients (RTR). Current recommendations advise fasting blood glucose (FBG) as the screening and diagnostic test of choice for PTD. This study sought to determine (1) the predictive power of FBG with respect to 2-h blood glucose (2HBG) and (2) the prevalence of PTD using FBG and 2HBG compared with that using FBG alone, in prevalent RTR. A total of 200 RTR (mean age 52 yr; 59{\%} male; median transplant duration 6.6 yr) who were >6 mo posttransplantation and had no known history of diabetes were studied. Patients with FBG",
author = "Armstrong, {Kirsten A.} and Prins, {Johannes B.} and Beller, {Elaine M.} and Campbell, {Scott B.} and Hawley, {Carmel M.} and Johnson, {David W.} and Isbel, {Nicole M.}",
year = "2006",
month = "1",
doi = "10.2215/CJN.00090605",
language = "English",
volume = "1",
pages = "100--108",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "1",

}

Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? / Armstrong, Kirsten A.; Prins, Johannes B.; Beller, Elaine M.; Campbell, Scott B.; Hawley, Carmel M.; Johnson, David W.; Isbel, Nicole M.

In: Journal of the American Society of Nephrology : JASN, Vol. 1, No. 1, 01.2006, p. 100-108.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Should an oral glucose tolerance test be performed routinely in all renal transplant recipients?

AU - Armstrong, Kirsten A.

AU - Prins, Johannes B.

AU - Beller, Elaine M.

AU - Campbell, Scott B.

AU - Hawley, Carmel M.

AU - Johnson, David W.

AU - Isbel, Nicole M.

PY - 2006/1

Y1 - 2006/1

N2 - Posttransplantation diabetes (PTD) contributes to cardiovascular disease and graft loss in renal transplant recipients (RTR). Current recommendations advise fasting blood glucose (FBG) as the screening and diagnostic test of choice for PTD. This study sought to determine (1) the predictive power of FBG with respect to 2-h blood glucose (2HBG) and (2) the prevalence of PTD using FBG and 2HBG compared with that using FBG alone, in prevalent RTR. A total of 200 RTR (mean age 52 yr; 59% male; median transplant duration 6.6 yr) who were >6 mo posttransplantation and had no known history of diabetes were studied. Patients with FBG

AB - Posttransplantation diabetes (PTD) contributes to cardiovascular disease and graft loss in renal transplant recipients (RTR). Current recommendations advise fasting blood glucose (FBG) as the screening and diagnostic test of choice for PTD. This study sought to determine (1) the predictive power of FBG with respect to 2-h blood glucose (2HBG) and (2) the prevalence of PTD using FBG and 2HBG compared with that using FBG alone, in prevalent RTR. A total of 200 RTR (mean age 52 yr; 59% male; median transplant duration 6.6 yr) who were >6 mo posttransplantation and had no known history of diabetes were studied. Patients with FBG

U2 - 10.2215/CJN.00090605

DO - 10.2215/CJN.00090605

M3 - Article

VL - 1

SP - 100

EP - 108

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 1

ER -